- Clinical Trials
- April 2025
- 80 Pages
Global
From €1791EUR$2,000USD£1,527GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2239EUR$2,500USD£1,909GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1791EUR$2,000USD£1,527GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1344EUR$1,500USD£1,145GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1120EUR$1,250USD£954GBP
- Drug Pipelines
- April 2025
- 40 Pages
Global
From €1120EUR$1,250USD£954GBP
- Drug Pipelines
- July 2024
- 100 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Report
- March 2025
- 185 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- March 2025
- 182 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- February 2025
- 180 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- January 2025
- 180 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- August 2024
- 185 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- July 2024
- 185 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- May 2025
- 110 Pages
Global
From €4255EUR$4,750USD£3,627GBP
- Report
- July 2024
- 110 Pages
Global
From €4255EUR$4,750USD£3,627GBP
- Report
- March 2025
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- December 2024
- 150 Pages
Global
From €3538EUR$3,950USD£3,016GBP
- Report
- December 2024
- 55 Pages
Global
From €2238EUR$2,499USD£1,908GBP
- Report
- April 2025
- 220 Pages
Global
From €1789EUR$1,997USD£1,525GBP
- Report
- February 2025
- 135 Pages
Global
From €3910EUR$4,365USD£3,333GBP
€4344EUR$4,850USD£3,703GBP

CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells.
CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors.
CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more